Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, et al. Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response. Clin Cancer Res 2021 Dec 3. pii: 1078-0432.CCR-21-3231.
PMID: 34862246